Epizyme, Inc.
EPZM evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for EPZM—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2022.
Tracking 2 pipeline candidates · 13 clinical trials · 1 FDA decision for Epizyme, Inc..
Run Epizyme, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Epizyme, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
8.5 months
OCF -$55M · Net income -$36M
Lead: Phase 3
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Frequently asked questions
What is Epizyme, Inc.'s lead drug candidate?
Epizyme, Inc.'s most advanced tracked candidate is ezm0414 (Phase 1) for Multiple Myeloma, Refractory.
Who is the CEO of Epizyme, Inc.?
Grant Bogle is the chief executive officer of Epizyme, Inc. (EPZM).
What therapeutic areas does Epizyme, Inc. focus on?
Epizyme, Inc. develops therapies across Oncology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.